TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36326797

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 20
Study: 36326854

Group type: EXPERIMENTAL
Intervention: ePRO system for AA and PNH patients
Number of subjects: 9
Study: 36326921

Group type: EXPERIMENTAL
Intervention: Commercial NPWT in America (77.4%) and Europe (52.3%)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Definitive abdominal closure in America (82.3%, fascial closure in 90.2%)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Prosthesis use in Europe (17.3%)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Overall morbidity rates
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Overall mortality rates
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Median open abdomen duration
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Overall ICU length-of-stay
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Overall hospital length-of-stay
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Overall entero-atmospheric fistula rate
Number of subjects: 1183
Study: 36327059

Group type: EXPERIMENTAL
Intervention: PVI + PWI ablation strategy with mandatory repeat procedures
Number of subjects: 24
Study: 36327094

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Filgotinib (FIL)
Number of subjects: 1755
Study: 36327344

Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix trifocal IOL (TFNT00)
Number of subjects: 2

Group type: COMPARATOR
Intervention: AcrySof monofocal IOL (SN60AT)
Number of subjects: 2
Study: 36327378

Group type: EXPERIMENTAL
Intervention: Family-Based Treatment delivered by videoconferencing (FBT-V)
Number of subjects: 21
Study: 36327624

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 0
Study: 36328033

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus FOLFOX (intravenous trastuzumab-pkrb at 6 mg/kg on day 1, FOLFOX regimen with intravenous oxaliplatin [85 mg/m2])
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus FOLFOX
Number of subjects: 34
Study: 36328377

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, followed by nivolumab 480 mg every 4 weeks for up to 2 years or until progression, toxicity, or protocol-specified discontinuation.
Number of subjects: 46
Study: 36328378

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 36328388

Group type: EXPERIMENTAL
Intervention: Audible waveform assessment
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Visual waveform assessment
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Ankle brachial pressure index (ABPI)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Exercise ABPI
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Toe brachial pressure index (TBPI)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Point-of-care duplex ultrasound scan (PAD-scan)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Reference tests (CT angiography or magnetic resonance angiography)
Number of subjects: 730
Study: 36328399

Group type: EXPERIMENTAL
Intervention: Three-dose primary SARS-CoV-2 vaccination in patients with IMID
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Two-dose primary SARS-CoV-2 vaccination in healthy controls
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Third dose of vaccination
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Comparison of antibody decline rates
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Adverse events in patients with IMID
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Adverse events in healthy controls
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Disease flares in patients with IMID
Number of subjects: 1100
Study: 36328395

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Desethylhydroxychloroquine (DHCQ)
Number of subjects: 25
Study: 36328438

Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccines
Number of subjects: 0
Study: 36328690

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 40670

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 40670

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 40670

Group type: COMPARATOR
Intervention: In-hospital mortality for IHCA patients
Number of subjects: 40670

Group type: COMPARATOR
Intervention: IHCA as a percentage of inpatient deaths
Number of subjects: 40670
Study: 36328851

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone and case management services
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naltrexone continuation after trial
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline daily alcohol consumption
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline quality of life
Number of subjects: 32
Study: 36328903

Group type: EXPERIMENTAL
Intervention: Avelumab maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 36329042

Group type: EXPERIMENTAL
Intervention: Periodontal pathobionts (specifically Porphyromonas gingivalis)
Number of subjects: 0
Study: 36329070

Group type: EXPERIMENTAL
Intervention: Females on dialysis
Number of subjects: 4994

Group type: COMPARATOR
Intervention: Males on dialysis
Number of subjects: 4994

Group type: COMPARATOR
Intervention: All-cause mortality for females vs males
Number of subjects: 4994

Group type: COMPARATOR
Intervention: Mortality due to sudden death, cancer, other, or unknown causes for females vs males
Number of subjects: 4994

Group type: COMPARATOR
Intervention: Mortality in patients on HD (females vs males)
Number of subjects: 4994

Group type: COMPARATOR
Intervention: Mortality in patients on PD (females vs males)
Number of subjects: 4994
Study: 36329083

Group type: EXPERIMENTAL
Intervention: Motor imagery training (MIT) of goal-directed reaching for four weeks.
Number of subjects: 27
Study: 36329366

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 55
Study: 36329414

Group type: EXPERIMENTAL
Intervention: Nurse-led anthropometric and oropharyngeal measurements combined with STOP-Bang questionnaire
Number of subjects: 761

Group type: COMPARATOR
Intervention: STOP-BANG Questionnaire (SBQ)
Number of subjects: 761

Group type: COMPARATOR
Intervention: Waist circumference
Number of subjects: 761

Group type: COMPARATOR
Intervention: Micrognathia
Number of subjects: 761
Study: 36329512

Group type: EXPERIMENTAL
Intervention: Severe OSA (apnoea-hypopnea index ≥30/h)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lipidomic profiling
Number of subjects: 103
Study: 36330013

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (including drug-coated balloon, directional atherectomy, supera, and drug-eluting stent)
Number of subjects: 600
Study: 36330105

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 0
Study: 36330140

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WGW) intervention (98 g/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Refined wheat (RW) intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WGW) intervention
Number of subjects: 50
Study: 36330484

Group type: EXPERIMENTAL
Intervention: Buparlisib, an oral pan-PI3K inhibitor, administered for a median of 4.5 months (range 2-33).
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Buparlisib, an oral pan-PI3K inhibitor.
Number of subjects: 14
Study: 36330490

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Apatinib 750 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Apatinib 850 mg
Number of subjects: 60
Study: 36330525

Group type: EXPERIMENTAL
Intervention: Arginase-1 peptide vaccine (three 20-mer peptides from the ARG1 immunological 'hot spot' region with Montanide ISA-51 adjuvant, administered subcutaneously every third week, maximum 16 vaccines)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arginase-1 peptide vaccine
Number of subjects: 10
Study: 36331157

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy-guided lymph node dissection
Number of subjects: 162

Group type: COMPARATOR
Intervention: Extended pelvic lymph node dissection (reference standard)
Number of subjects: 162
Study: 36331190

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6609
Study: 36331539

Group type: EXPERIMENTAL
Intervention: FREEDoM app-based mHealth intervention
Number of subjects: 11
Study: 36331547

Group type: EXPERIMENTAL
Intervention: Technology-based obesity prevention interventions
Number of subjects: 7
Study: 36331674

Group type: EXPERIMENTAL
Intervention: Orally-administered bendamustine hydrochloride, dosages ranging from 175 to 840 mg/m2, administered once daily for 7, 14, and 21 days every 3 weeks as one cycle.
Number of subjects: 0
Study: 36331676

Group type: EXPERIMENTAL
Intervention: CA102N (0.72 mg/kg Nim equivalent)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CA102N in combination with trifluridine-tipiracil
Number of subjects: 37
Study: 36331681

Group type: EXPERIMENTAL
Intervention: First-line cryoballoon ablation (CBA)
Number of subjects: 1394

Group type: COMPARATOR
Intervention: CBA in antiarrhythmic drug (AAD)-refractory patients
Number of subjects: 1394
Study: 36332004

Group type: EXPERIMENTAL
Intervention: NKTR-255 + CD19 CAR T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD19 CAR T cells alone
Number of subjects: 0
Study: 36332294

Group type: EXPERIMENTAL
Intervention: MRD positivity defined as ≥ 0.1% of leukemic bone marrow cells
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Integrated molecular risk classification
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: MRD status
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Expression of CD25 by leukemic myeloblasts at diagnosis
Number of subjects: 189
Study: 36332560

Group type: EXPERIMENTAL
Intervention: Bacterial fluorescence imaging
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 80
Study: 36332645

Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: nOPV2
Number of subjects: 91
Study: 36332763

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg and 300 mg every 2 weeks
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 1902
Study: 36332953

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir/emtricitabine (TDF/FTC) with adherence self-management interventions (point-of-care urine drug-level assay, HIV self-testing, weekly text messaging)
Number of subjects: 120
Study: 36332964

Group type: EXPERIMENTAL
Intervention: IL-6 antagonist therapy
Number of subjects: 0
Study: 36333014

Group type: EXPERIMENTAL
Intervention: healthful plant-based diet index (hPDI)
Number of subjects: 11825

Group type: COMPARATOR
Intervention: unhealthful plant-based diet index (uPDI)
Number of subjects: 11825
Study: 36333128

Group type: EXPERIMENTAL
Intervention: FETO
Number of subjects: 18

Group type: COMPARATOR
Intervention: non-FETO
Number of subjects: 18
Study: 36333289

Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS)
Number of subjects: 218
Study: 36333463

Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine (Cami)
Number of subjects: 0
Study: 36333464

Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine (Cami); specific dosage and duration not mentioned.
Number of subjects: 0
Study: 36333533

Group type: EXPERIMENTAL
Intervention: Celtra Duo (CD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: e.max CAD (EMA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: UP.CAD (UP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enamic (ENA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyramic (HY)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: InCoris TZI (ZIR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zirconia (ZIR)
Number of subjects: 10
Study: 36333616

Group type: EXPERIMENTAL
Intervention: Worst Pruritus Numerical Rating Scale (WP-NRS)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Symptom Scale (ADerm-SS) 7-Item Total Symptom Score (TSS-7)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Impact Scale (ADerm-IS) Sleep
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Impact Scale (ADerm-IS) Daily Activities
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Impact Scale (ADerm-IS) Emotional State
Number of subjects: 882
Study: 36333619

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) sessions on a cycle ergometer for 4 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diagnostic model using five affected parameters
Number of subjects: 11
Study: 36333618

Group type: EXPERIMENTAL
Intervention: Spesolimab 600-mg loading dose followed by 300-mg maintenance dose every 4 weeks
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Spesolimab 600-mg loading dose followed by 300-mg maintenance dose every 12 weeks
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Spesolimab 300-mg loading dose followed by 150-mg maintenance dose every 12 weeks
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 36333676

Group type: EXPERIMENTAL
Intervention: Glucose control treatment group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Good collaterals
Number of subjects: 57

Group type: COMPARATOR
Intervention: Poor collaterals
Number of subjects: 57
Study: 36333682

Group type: EXPERIMENTAL
Intervention: Point-of-care CRP testing
Number of subjects: 8280
Study: 36333718

Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS) based diagnostics
Number of subjects: 200
Study: 36333746

Group type: EXPERIMENTAL
Intervention: Robotic-assisted early mobilization
Number of subjects: 30
Study: 36333889

Group type: EXPERIMENTAL
Intervention: Nocturnal wearing of dentures
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no dentures)
Number of subjects: 65
Study: 36334048

Group type: EXPERIMENTAL
Intervention: High-dose oral glutamine supplementation
Number of subjects: 9
Study: 36334053

Group type: EXPERIMENTAL
Intervention: Preterm group (n=202)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Term group (n=172)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Pregnancies complicated by threatened preterm labor or premature rupture of membranes
Number of subjects: 374
Study: 36334163

Group type: EXPERIMENTAL
Intervention: Urgency NRS
Number of subjects: 1162
Study: 36334236

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab 45/90 mg
Number of subjects: 0
Study: 36334289

Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound (FUS) treatment targeting the hippocampus, frontal lobe, and parietal lobe, with 3 separate treatment sessions performed 2 weeks apart.
Number of subjects: 10

Group type: COMPARATOR
Intervention: MRI-guided focused ultrasound (FUS) treatment
Number of subjects: 10
Study: 36334312

Group type: EXPERIMENTAL
Intervention: KCCQ-12 assessment
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1248
Study: 36335079

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy from the quitline
Number of subjects: 1944

Group type: EXPERIMENTAL
Intervention: Any pharmacotherapy
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Nicotine replacement therapy receipt
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Nicotine replacement therapy use
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Quitting by insurance classifications
Number of subjects: 1944
Study: 36335120

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus pembrolizumab with anastrozole (cohort 1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus pembrolizumab without anastrozole (cohort 2)
Number of subjects: 54
Study: 36335217

Group type: EXPERIMENTAL
Intervention: gedatolisib (180 mg QW) plus cisplatin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: gedatolisib (90-310 mg QW) plus docetaxel
Number of subjects: 110
Study: 36335235

Group type: EXPERIMENTAL
Intervention: Septic shock (S group)
Number of subjects: 50
Study: 36335366

Group type: EXPERIMENTAL
Intervention: Compulsive Exercise Test (CET)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: CET total score
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Body mass index, weight loss attempts, physical fitness
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Introjected motivational regulation, HRQoL subscale parent relation and autonomy, exercise monitoring tool usage, weight loss attempts
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Physical activity level
Number of subjects: 572
Study: 36335479

Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (500 mg once daily)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 36335531

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (cross-over to mavacamten from week 16 to week 32)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Mavacamten (cross-over group after 16 weeks)
Number of subjects: 112
Study: 36335910

Group type: EXPERIMENTAL
Intervention: Elderly age (≥65 years)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: First medical contact (FMC) prior to attending the ED
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Women older than 65 years
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Atypical presentation in women and elderly patients
Number of subjects: 330
Study: 36335915

Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg BID)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) phenprocoumon (INR 2.0 to 3.0)
Number of subjects: 97
Study: 36336198

Group type: EXPERIMENTAL
Intervention: Machine-learning-estimated structural progression score (s-score)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Cartilage thickness loss
Number of subjects: 270
Study: 36336468

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 76
Study: 36336644

Group type: EXPERIMENTAL
Intervention: Management changes including acid suppression (30%) and thickened feedings (27%)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallow study
Number of subjects: 124
Study: 36336684

Group type: EXPERIMENTAL
Intervention: Hepatic steatosis (measured by liver fat fraction using MRI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Degree of liver fibrosis (measured by ELF test)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measures (HOMA2S, Matsuda ISI, MinMod SI)
Number of subjects: 100
Study: 36336750

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 175
Study: 36336899

Group type: EXPERIMENTAL
Intervention: Tumor treating fields (TTFields) with concurrent chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tumor treating fields (TTFields)
Number of subjects: 0
Study: 36336905

Group type: EXPERIMENTAL
Intervention: Self-guided walking program (at least 30 minutes or 6200 steps/day)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Self-guided walking program
Number of subjects: 141
Study: 36337036

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) <2.0 (55.2% of patients)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Low CFR
Number of subjects: 67
Study: 36337437

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) 500 mg/day for 6 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) 500 mg/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) and Placebo
Number of subjects: 121
Study: 36337613

Group type: EXPERIMENTAL
Intervention: Resistant starch type 4 (RS4) intake of 12 g/day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specifics not provided)
Number of subjects: 0
Study: 36337708

Group type: EXPERIMENTAL
Intervention: Post-COVID condition group
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment, digit symbol test, phonetic verbal fluency
Number of subjects: 428

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Post-COVID condition individuals with cognitive complaints
Number of subjects: 428
Study: 36337904

Group type: EXPERIMENTAL
Intervention: Long drug-eluting stents (DES)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Spot drug-eluting stents (DES)
Number of subjects: 103
Study: 36338165

Group type: EXPERIMENTAL
Intervention: Cobalt chromium everolimus-eluting stent (EES)
Number of subjects: 7823

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stent
Number of subjects: 7823

Group type: EXPERIMENTAL
Intervention: Platinum chromium-EES
Number of subjects: 7823

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent
Number of subjects: 7823
Study: 36338359

Group type: EXPERIMENTAL
Intervention: Whole vessel plaque quantification
Number of subjects: 1013

Group type: COMPARATOR
Intervention: % diameter stenosis and high-risk plaque characteristics (HRPC)
Number of subjects: 1013
Study: 36338362

Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting stent (DES)
Number of subjects: 5498

Group type: COMPARATOR
Intervention: First-generation drug-eluting stent (DES)
Number of subjects: 5498